Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incobotulinumtoxin A versus Onabotulinumtoxin A in neurogenic overactive bladder
2016-003949-28Phase 3Terminated
- Sponsor
- University of Perugia
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of botulinum toxin type A in neurogenic bladder, overactive bladder (OAB) and Functional bladder disorder (2 arms), sponsored by University of Perugia. Primary endpoint: Reduction in urinary incontinence episodes. Started Jun 2021; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic bladderoveractive bladder (OAB)Functional bladder disorder
Beyond the preview
Go deeper on 2016-003949-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003949-28.